Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2004 (First Quarter of Fiscal 2004)
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (contact lenses) and CooperSurgical (medical devices for gynecology and obstetrics).
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales | $109,734 | $94,014 |
| Gross Profit | $69,956 | $59,367 |
| Gross Margin | 64% | 63% |
| Operating Income | $24,849 | $19,819 |
| Net Income | $18,355 | $13,855 |
| Diluted EPS | $0.55 | $0.44 |
| Cash from Operations | $6,809 | $3,112 |
| Cash & Equivalents (End) | $45,324 | $9,054 |
| Total Debt | $182,056 | $185,861 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($15.7 million) year-over-year, driven by a 19% increase in CooperVision and a 7% increase in CooperSurgical. Constant currency growth was 10%.
- Profitability: Operating income rose 25% to $24.9 million. Diluted earnings per share increased 25% to $0.55.
- Segment Performance:
- CooperVision: Specialty lens revenue (toric, cosmetic, multifocal) grew 30%, now comprising 64% of soft lens revenue. International sales grew 22%.
- CooperSurgical: Revenue grew 7%, with 3% organic growth. Margin improved to 54% from 50% due to acquisition integration efficiencies.
- Cash Flow: Operating cash flow more than doubled to $6.8 million. Investing cash outflows were $9.9 million, primarily for capital expenditures ($6.9 million) and acquisitions ($5.1 million).
- Working Capital: Increased by $23.4 million, largely due to higher inventory levels (7.5 months on hand) to address prior capacity constraints.
Guidance, Outlook, and Risks
- Outlook: Management expects fiscal 2004 capital expenditures of approximately $45 million to double U.K. manufacturing capacity. The company anticipates an effective tax rate of 23% for fiscal 2004, down from 24% in 2003, due to a shift in business mix to lower-tax jurisdictions.
- Liquidity: The company maintains $45.3 million in cash and $143.1 million in available credit under its KeyBank facility. Management believes current resources will fund operations, dividends, and smaller acquisitions.
- Recent Acquisitions (Subsequent Events):
- Milex Products, Inc. (Feb 2, 2004): Acquired for ~$26 million; adds obstetric/gynecologic products.
- Argus Biomedical assets (Feb 23, 2004): Acquired for ~$2.1 million; includes AlphaCor artificial cornea.
- Risks: Exposure to foreign exchange fluctuations (pound sterling and euro), interest rate changes on variable debt, regulatory issues (product recalls), and integration risks from acquisitions.
Investor Verification Checklist
- Inventory Levels: Verify the rationale for the increase in inventory months-on-hand (7.5 vs. 7.0) and potential obsolescence risks.
- Acquisition Integration: Monitor the financial impact and integration progress of the Milex and Argus acquisitions completed in February 2004.
- Foreign Currency Impact: Assess the sensitivity of future margins to exchange rate fluctuations, particularly given significant manufacturing in the U.K.
- Debt Structure: Review the terms of the $115 million convertible senior debentures due in 2023 and the $210.9 million KeyBank facility maturing in 2007.
- Stock-Based Compensation: Note that reported EPS excludes stock-based compensation costs; pro forma diluted EPS was $0.52 versus reported $0.55.